Marina Biotech this week announced that the Intellectual Property Office of New Zealand said it will grant the company a patent covering its unlocked nucleobase analog technology.

The deal with an undisclosed "major pharmaceutical company" is focused on the evaluation of Marina's proprietary amphoteric liposomal formulations for pulmonary delivery.

According to MDRNA, the application claims siRNAs and delivery systems with therapeutic potential.

An opinion piece in the Guardian argues that President Donald Trump is uninterested in science and that might not be a bad thing for the field.

The San Francisco Chronicle reports the Veterans Affairs Health System is studying whether genetic testing can help prescribe better depression therapies.

Stat News reports that Spark Therapeutics' Luxturna is now being used to treat a wider array of patients.

In Genome Biology this week: transcription factor use among brittle stars, single-cell RNA sequencing strategy, and more.